Cookies Policy

1. Introduction

This Cookies Policy informs about the cookies or similar technologies that are or may be installed in your device when accessing and using this website (the "Site") operated by Grifols USA, LLC (the “Company”).

From now on, this Cookies Policy uses the term "cookies" to refer to cookies and similar technologies, such as pixels, web beacons or digital fingerprinting techniques.

This Site may use cookies that lead to the processing of your personal data. Please visit the Privacy Notice for information on how the Company processes your personal data when using cookies.

2. What are cookies?

A cookie is a file that is downloaded in your device when you access certain websites or electronic communications. Cookies allow a webpage to store and retrieve, among other things, information on the number of visits and the browsing behavior of users or of their devices.

Cookies are used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.

3. What type of cookies uses this Site?

In general terms, cookies can be classified as follows:

  1. Essential: these are strictly necessary for the Site to work and to permit the browsing of the Site as requested. Some examples are activating basic functions such as page navigation and access to secure website areas or customizing the Site presentation (e.g. language). Without these cookies, the Site would not be able to work properly.
  2. Non-essential: these are all other cookies not falling within the prior category and includes analytical cookies. These cookies are installed in your device only after your express consent.

Essential and non-essential cookies of this Site can be classified following these criteria:

  1. Duration:
    • Session: these expire at the end of a browser session (normally when you exit the browser or turn off your device).
    • Persistent: these are stored in your device for a longer period than the browser session. The duration of persistent cookies is set by the responsible of the cookie and can be from some minutes to several years.
  2. Entity placing the cookie:
    • First-party: these are set directly by the Site.
    • Third-party: these are set by other websites different from the Site and typically occurs when the Site incorporates elements from other websites (such as images or social media plugins) or when engaging third parties to provide services to the Company through the Site.
  3. Purposes:
    • Strictly Necessary Cookies: these cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
    • Functional Cookies: these cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.
    • Performance Cookies: these cookies allow us to count visits and traffic sources to understand how our visitors interact with the site, so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.
    • Targeting Cookies: these cookies may be set through our site by our advertising partners. they may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store personal information that directly identify you but are based on uniquely identifying your browser and internet device.
    • Social Media Cookies: these cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit.

Please find below further details on the cookies used in this Site:

4. How to disable or delete cookies?

You can withdraw your consent to the use of cookies or modify your cookies preferences at any time by clicking this link:

Change my cookie settings

Additionally, you may enable, block or delete the cookies installed in your device through the settings of your browser. We inform you that disabling essential cookies may have an impact on the proper functioning of the Site.

Information on how to manage or disable cookies on the main browsers is available below:

  • For Google Chrome, click here.
  • For Firefox, click here.
  • For Microsoft Edge, click here.
  • For Opera, click here.
  • For Safari, click here.

We remind you of the importance to access the last updated support information of said browsers in order to know how you can manage and delete cookies. In case you use any other Internet browser, please visit the settings of the relevant browser.

To opt out of being tracked by Google Analytics across all websites, visit http://tools.google.com/dlpage/gaoptout.

5. Modification of the Cookies Policy

The Company may totally or partially modify this Cookies Policy if required by applicable legislation or in order to adjust the Policy to the cookies actually used in the Site and any related electronic communications.

Date of creation: January 2024

Important Safety Information for HyperRHO® S/D Mini-Dose (Rhₒ[D] immune globulin [human])

HyperRHO® S/D Mini-Dose (RhO[D] immune globulin [human]) is recommended to prevent the isoimmunization of RhO(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation provided the following criteria are met:

  1. The mother must be RhO(D) negative and must not already be sensitized to the RhO(D) antigen.
  2. The father is not known to be RhO(D) negative.
  3. Gestation is not more than 12 weeks at termination.

HyperRHO S/D Mini-Dose is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

NEVER ADMINISTER HYPERRHO S/D MINI-DOSE INTRAVENOUSLY. INJECT ONLY INTRAMUSCULARLY. ADMINISTER ONLY TO WOMEN POSTABORTION OR POSTMISCARRIAGE OF UP TO 12 WEEKS' GESTATION. NEVER ADMINISTER TO THE NEONATE.

HyperRHO S/D Mini-Dose should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations.

The attending physician who wishes to administer HyperRHO S/D Mini-Dose to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

Although systemic reactions to immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic symptoms.

Other antibodies in the HyperRHO S/D Mini-Dose preparation may interfere with the response to live vaccines such as measles, mumps, polio or rubella. Therefore, immunization with live vaccines should not be given within 3 months after HyperRHO S/D Mini-Dose administration.

Animal reproduction studies have not been conducted with HyperRHO S/D Mini-Dose. It is also not known whether HyperRHO S/D Mini-Dose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HyperRHO S/D Mini-Dose is not indicated for use during pregnancy and it should be administered only postabortion or postmiscarriage.

Safety and effectiveness in the pediatric population have not been established.

Reactions to HyperRHO S/D Mini-Dose are infrequent in RhO(D) negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human globulin is extremely rare, it has occurred.

Please see full Prescribing Information for HyperRHO S/D Mini-Dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Important Safety Information for HyperRHO® S/D Full Dose (Rhₒ[D] immune globulin [human])  

HyperRHO® S/D Full Dose (RhO[D] immune globulin [human]) is indicated for prevention of Rh hemolytic disease of the newborn (HDN) and the prevention of isoimmunization in RhO(D) negative individuals who have been transfused with RhO(D) positive red blood cells.

HyperRHO S/D Full Dose is made from human plasma. Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Never administer HyperRHO S/D Full Dose intravenously. Inject only intramuscularly. Never administer to the neonate.

RhO(D) immune globulin (human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

A large fetomaternal hemorrhage late in pregnancy or following delivery may cause a weak mixed field positive DU test result. If there is any doubt about the mother's Rh type, she should be given RhO(D) immune globulin (human). A screening test to detect fetal red blood cells may be helpful in such cases.

If more than 15 mL of D-positive red blood cells are present in the mother's circulation, more than a single dose of HyperRHO S/D Full Dose is required. Failure to recognize this may result in the administration of an inadequate dose.

Although systemic reactions to human immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic symptoms.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after RhO(D) immune globulin (human) administration.

HyperRHO S/D Full Dose should be given in pregnant women only if clearly needed because animal reproduction studies have not been conducted.

Reactions to RhO(D) immune globulin (human) are infrequent in RhO(D)-negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human immunoglobulin is extremely rare, it has occurred.

Elevated bilirubin levels have been reported in some individuals receiving multiple doses of RhO(D) immune globulin (human) following mismatched transfusions. This is believed to be due to a relatively rapid rate of foreign red cell destruction.

Please see full Prescribing Information for HyperRHO S/D Full Dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.